AVAILABLE MEDICINE FOR Ceritinib
There are no products to list.
Introduction to Ceritinib
Ceritinib is an anaplastic lymphoma kinase (ALK) inhibitor used in the treatment of non-small cell lung cancer (NSCLC). Ceritinib is a targeted cancer therapy drug belonging to the class of tyrosine kinase inhibitors. It was approved for its medical use on 29th April 2014.
How it Works:
Ceritinib inhibits the activity of the ALK mutation, a genetic alteration that drives cancer cell growth in certain types of NSCLC.
Uses:
Treatment of ALK-positive metastatic NSCLC.
Side Effects:
- Nausea, diarrhea
- elevated liver enzymes.
- Rare: lung toxicity
- QT prolongation.
